This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer

< Back

Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer


Cancer and Palliative Care

February 2018

Prostate cancer is cancer of the prostate gland (a small organ in a man’s pelvis) and is the second most common cancer in the UK. There are three stages: localised, locally‐advanced and advanced (or metastatic) prostate cancer. The symptoms may vary depending on the stage of cancer but can include pain, tiredness, problems emptying the bladder and the bowels. About half of men diagnosed with locally‐advanced prostate cancer will see their cancer spread to other body organs (i.e. becoming metastatic). Prostate cancer growth and spread depends on the hormone, testosterone. Cancer that do not respond to hormonal treatment to reduce the level of testosterone are known as castrationresistant prostate cancer.
Darolutamide is a hormonal drug under development for castration resistant prostate cancer that has not spread (non‐metastatic). It acts by blocking testosterone receptors from getting activated on the cancer cells and consequently reducing the size of the cancer. Darolutamide is taken orally twice a day. If licenced, darolutamide will provide an additional treatment option for men with non‐metastatic castration‐resistant prostate cancer that are at high risk of their cancer spreading to other parts of the body.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts